anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study represents a novel clinical trial strategy designed to assess both prospective "prophylactic" therapy for psychopathology in Alzheimer's disease (AD) and to assess an approach that may alter several aspects of the pathophysiology of AD, and perhaps result in alteration of clinical progression of illness. Interpretation of these results will be supported by study of relevant biomarkers and imaging data. Valproate was selected because of its possible symptomatic efficacy for agitation in AD, known safety profile in numerous clinical populations, and in view of recent data supporting its neuroprotective potential in AD. The primary hypothesis is that chronic valproate administration to participants with AD who lack agitation and psychosis at baseline will delay the emergence of agitation and/or psychosis. An effect of this nature may have significant public health implications, for instance, by delaying institutionalization.

This is a randomized, placebo-controlled, double blind, multicenter 26-month trial of valproate therapy at a target dose of 10-12 mg/kg/day in 300 outpatients with mild to moderate Alzheimer's Disease (AD) who lack agitation and psychosis at baseline and since onset of illness. Participants will have regular clinic visits as well as telephone contacts for assessment of behavior, cognition, function, safety and tolerability. The chief secondary aim is to determine whether valproate administration to participants with AD will attenuate clinical progression of illness measured by a reduced rate of cognitive or functional decline. In addition, issues related to safety and tolerability with low-dose (10-12 mg/kg/day) therapy will be addressed. Biological specimens will be obtained to study markers selected for their relevance to the disease as well as the postulated mechanism of action of the valproate therapy. Magnetic resonance imaging (MRI) scans will be performed prior to experimental treatment and after one year in a subset of participants in order to address possible drug-placebo differences in brain volume measures.

Approximately 300 participants from 25-35 clinical trial centers in the United States will be enrolled. Participation will include men and women with a diagnosis of probable Alzheimer's disease, age 55 or older, weighing at least 40 kg (88.2 lbs.), residing in the community at baseline, Mini Mental State Examination (MMSE) 10-20 inclusive, who have not experienced agitation or psychosis since the onset of their illness and who do not require treatment with psychotropic medications with the exception of antidepressants used only for treatment of depressive symptoms and limited use of sedatives for sleep. Participants, their relatives, guardians or authorized representatives and informants will be given ample opportunity to inquire about details of the study. Informed consent forms covering consent for the trial itself as well as the genetic research and biological sample storage and MRI scans will be provided to protect the patient's rights and confidentiality.
NSAIDs, including ketorolac tromethamine, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. NSAIDs can also cause fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of ketorolac tromethamine tablets at the first appearance of skin rash or any other sign of hypersensitivity. Ketorolac tromethamine tablets are contraindicated in patients with previous serious skin reactions to NSAIDs (see CONTRAINDICATIONS).
PURPOSE:To facilitate making consultation histories by automatically creating file names including information necessary for making the consultation histories on the basis of consultation data, and by only totalizing the file names, in recording the consultation data. CONSTITUTION:Necessary medical examination data are inputted from a keyboard 5 and stored in the memory MEM of an information processor 4. Then, the CPU of the information processor 4, judging each examination name based on the examination data within the memory MEM, determines two alphabetical letters corresponding to each examination name as the first two letters of the file name. Thereafter, the CPU takes out only the data corresponding to the year from the data of the consultation date and determines its last two figures as the third and fourth letters of the file name. Further, the CPU inserts the four figures in the consultation No. in the fifth to the eighth positions of the file name, and lastly inserts a code for the result of the examination in the last position to finalize the file name. The CPU records in an optical card the examination data and the determined file name within the memory MEM.
INTRODUCTION: Cataract surgery offers significant improvement to quality of life for patients with cataracts. However, there are growing waiting lists and challenges in providing this type of surgery in a timely manner. Feedback from stakeholders had previously indicated infection prevention and control (IPC) as a potential barrier to high-throughput surgery. Antimicrobial Resistance and Healthcare Associated Infection Scotland was asked to support the implementation of high-throughput cataract surgery aimed at addressing these challenges.
AIM: To develop an IPC pathway to facilitate high-throughput surgery. This would be based on best practice, and would address any barriers identified by stakeholders.
METHODS: A short life working group with input from key stakeholders, including clinical teams, was established. A rapid literature review was also undertaken.
RESULTS: An agreed patient pathway was developed, with the aim of helping to facilitate high-throughput surgery. Pre-, intra- and postoperative phases were considered. Where literature was unavailable, expert/consensus opinion was utilized. Facilities for high-throughput surgery were also considered, including the Jack and Jill theatre arrangement which lends itself well to this concept.
CONCLUSION: Through collaboration with stakeholders, an IPC pathway was developed to facilitate high-throughput cataract surgery and address any potential IPC barriers to implementation. The process and the output described could be utilized to develop similar pathways for other surgeries that lend themselves well to high throughput, improving quality of life for patients and reducing waiting times. This study highlights the importance of establishing surveillance for postoperative endophthalmitis following implementation.
Elastic stockinette was applied as protective filling material. Standard 250 mmHg pressure was applied as pneumatic tourniquet pressure.
Deferoxamine, an iron chelator used to treat diseases caused by excess iron, has had a Food and Drug Administration-approved status for many years. A large number of studies have confirmed that deferoxamine can reduce inflammatory response and promote angiogenesis. Blood vessels play a crucial role in sustaining vital life by facilitating the delivery of immune cells, oxygen, and nutrients, as well as eliminating waste products generated during cellular metabolism. Dysfunction in blood vessels may contribute significantly to the development of life-threatening diseases. Anti-angiogenesis therapy and pro-angiogenesis/angiogenesis strategies have been frequently recommended for various diseases. Herein, we describe the mechanism by which deferoxamine promotes angiogenesis and summarize its application in chronic wounds, bone repair, and diseases of the respiratory system. Furthermore, we discuss the drug delivery system of deferoxamine for treating various diseases, providing constructive ideas and inspiration for the development of new treatment strategies.
INTRODUCTION: Tobacco smoking is linked to an elevated risk of osteomyelitis and delayed healing in long bone fractures. However, the impact of smoking on bone union and soft tissue recovery following ankle fractures remains unclear. This study presents a retrospective comparative analysis evaluating the effects of chronic heavy tobacco smoking on the healing process and outcomes of ankle fractures after surgical interventions.
MATERIALS AND METHODS: We examined 220 consecutive cases of chronic heavy smokers (CHS) with closed ankle fractures who were referred to our unit for further treatment. A control group, consisting of 220 age- and sex-matched individuals (non-smokers with closed ankle fractures), was identified for comparative analysis. We collected clinical data, including pre-existing comorbidities, Lauge-Hansen fracture classification, necessity for surgery, and the surgical procedures performed. The primary outcomes investigated were the time required for fracture union and wound healing. Secondary outcomes included postoperative complications such as prolonged pain, bleeding, swelling, infection, compartment syndrome, and neurovascular impairment, as well as the incidence of delayed union, non-union, and the need for further intervention. Both cohorts were monitored for a minimum of 24 months.
RESULTS: Our analysis revealed that the surgical cohort of chronic heavy smokers exhibited a statistically significant delay in fracture union compared to both the conservatively managed smokers and the control group. Further scrutiny of the surgical cohort of chronic smokers indicated a significant correlation between smoking and extended postoperative pain duration, persistent swelling at the fracture site, and both superficial and deep wound infections. Additionally, these patients experienced delays in both fracture union and wound healing when compared to the control group. Similarly, the conservatively managed chronic smokers showed a marginal increase in the incidence of post-injury pain duration, extended swelling at the fracture site, and delayed union compared to the control group.
CONCLUSION: Patients who are chronic heavy smokers and require surgical intervention for ankle fractures should be made aware of their increased risk for delayed fracture union and poor wound healing. Orthopedic surgeons should proactively encourage these patients to participate in smoking cessation programs.
PURPOSE:To provide a new compound having DNA topoisomerase inhibitory activity, useful as an oncotherapeutic agent. CONSTITUTION:The objective compound of formula I [X and Y are each H, mercapto or lower alkylthio, being combined into (S)n (n is 1-4); Z is H or (substituted) carbamoyl] or a salt thereof, e.g. TAN-1496A of formula II. The compound of the formula I can be obtained from a product which is formed by culture of microorganisms belongning to Microspheropsis and halving ability to produce a compound of formula III (n' is 2-4) (e.g. Microspheropsis sp. FL-16144 strain) in a liquid medium (pref. adjusted to pH 5 to 8) at 20-30 deg.C for 48-144hr.
This pilot study will utilize an intra-patient dose escalation design. Cycles are 28 days in length. Subjects will receive lenalidomide 2.5 mg weekly during days 1 to 21 of cycle 1 (dose level 1). If patients do not experience any grade \> 3 hematologic or non-hematologic toxicity, the dose will be increased to 2.5 mg twice weekly on days 1 to 21 of cycle 2 (dose level 2). If patients do not experience any grade \> 3 hematologic or non-hematologic toxicity, the dose will be increased to 5 mg twice weekly on days 1 to 21 of cycle 3 (dose level 3). If patients do not experience any grade \>3 hematologic or non-hematologic toxicity, the dose will be increased to 5 mg thrice weekly on days 1 to 21 of cycle 4 (dose level 4). Patients who experience grade \>3 hematologic or non-hematologic toxicity at dose level 1 will be discontinued from study. Patients who experience grade \> 3 hematologic or non-hematologic toxicity at dose level 2, 3, or 4 will have the lenalidomide held and dose reduced according to protocol dose interruption/modification algorithms (section 5.5.3). If at least a minor erythroid response is not achieved at the end of 8 cycles of treatment, patients will be discontinued from study. If a minor or major erythroid response is achieved after completion of 8 cycles of treatment, patients can continue study drug on a maintenance phase until loss of erythroid response (return to baseline hemoglobin or transfusion requirement) or unacceptable toxicity.
FIELD: medicine, narcology. SUBSTANCE: at the first stage method involves suggestive psychotherapy with motivation for complete recovery and refusal from intake of alcohol and/or narcotic substances. At the second stage disintoxification therapy is carried out for 13-15 days that involves deep purgation of intestines with medicinal plant extracts-base aqueous solutions+ADs- intravenous administration of the preparation +ACI-hemodes+ACI- based on polyvinylpyrrolidone in amount 400-800 ml every day and 10+ACU- solution of ascorbic acid prepared on physiological solution and/or water as measured 100-120 g of dry substance per 24 +ADs- oral administration of mixture by 100 ml, 4 times per a day and ascorbic acid in amount 15-20 g/day. At the third stage supporting phytotherapy is carried out for 2.5-3 months by oral administration of medicinal plant infusions. Mixture based on sodium chloride an aqueous solution and ascorbic acid has vitamin B 6 , euphylline, corglycon, dimedrol, relanium, furosemide, nootropil and magnesium sulfate solution. EFFECT: enhanced effectiveness of treatment. 4 cl
Functional vision disorder (FVD) is a relatively common diagnosis in ophthalmic practice which can be difficult to make because of clinician's apprehension to miss organic pathology. We review the diagnostic approach to patients with FVD, organic mimics of FVD, its diagnostic and management strategies and associated cost burden. Patients with FVD typically present with visual acuity and/or field loss. Diagnostic work-up should include patient observation, detailed history, pupillary examination, dilated ophthalmoscopy, visual field testing and ganglion cell analysis of the macular complex. Most common organic mimickers of FVD are amblyopia, cortical blindness, retrobulbar optic neuritis, cone dystrophy and chiasmal tumours; however, all could be ruled out by structured diagnostic approach. For patients with unilateral visual loss, bottom-up refraction, fogging of the well-seeing eye in the phoropter, convex lens and base-down prism tests could aid in diagnosis. For patients claiming binocular vision loss, checking for eye movement during the mirror test or nystagmus elicited by an optokinetic drum can be helpful. Effective management of FVD involves reassurance, stress reduction and, if agreed on, management of comorbid anxiety and/or depression. The social cost of FVD is predominately economic as patients typically meet several healthcare providers over multiple visits and often undergo several neuroimaging studies before neuro-ophthalmology referral. Further, inappropriate granting of disability benefits confers additional stigma to patients with organic vision loss.
The goal of the current research was to establish the impact of mental fatigue on the contributions of explicit (i.e., conscious strategy) and implicit (unconscious) processes to visuomotor adaptation. Participants were divided into two groups, a Mental Fatigue (MF) group who completed a cognitively demanding 32-minute time load dual back task (TLDB), and a Control group who watched a documentary for a similar length of time. Following the TLDB task or documentary watching, participants trained to reach with a visuomotor distortion, such that cursor feedback was rotated 40º clockwise relative to hand motion. Explicit and implicit contributions to visuomotor adaptation were assessed following 3 blocks of 45 rotated reach training trials and again following a 20-minute rest. Levels of mental fatigue, as indicated on a self-report scale, increased significantly for the MF group following the TLDB task. The Control group did not display a similar increase in mental fatigue following the documentary watching. Results then revealed a decrease in visuomotor adaptation early in training for the MF group compared to the Control group, as well as decreased retention of visuomotor adaptation immediately following the 20-minute rest. Furthermore, correlational analyses revealed that greater levels of mental fatigue reported by participants in the MF group were associated with less explicit adaptation and greater implicit adaptation. Similar trends were not observed for the Control group. Taken together, the decreased visuomotor adaptation observed early in training, as well as the moderate correlation between increased mental fatigue and decreased explicit adaptation, suggest that mental fatigue decreases one's ability to engage in explicit processing, limiting the overall extent of initial visuomotor adaptation achieved.
INTRODUCTION: Acute acoustic trauma (AAT) is characterized by cochlea-vestibular signs following intense noise exposure, often caused by impulse noise. French military faces a high risk of AAT because of the use of weapons with peak sound levels exceeding 150 dB. Hearing loss (HL) resulting from AAT can have a significant impact on quality of life and operational capacity. The aim of this study was to assess the prevalence of long-term hearing impairment after AAT.
MATERIALS AND METHODS: The study involved a retrospective review of computer-based patient records from four military medical centers in Northeast France between January 2016 and December 2021. The inclusion criteria required the presence of cochlea-vestibular signs following impulse acoustic exposure and the absence of other causes. Sociodemographic and clinical data were collected, including audiometric data before and after exposure. The primary end point was the presence of a threshold elevation greater than 10 dB between reference and late audiograms.
RESULTS: A total of 419 patients were included in the analysis, with a majority of males (n = 419; 84.7%) and a mean age of 23.6 yrs. The most common causative agent was the 5.56-mm assault rifle (n = 327; 78.0%). Tinnitus was the most frequent symptom (n = 366; 87.4%), followed by hypoacusis (n = 147; 35.1%) and earache (n = 89; 21.2%). The initial audiograms showed no HL in 31.0% of cases, while the mean deficit across all frequencies was 15.4 dB. All patients received corticosteroid therapy, with a mean duration of 6.0 d. Late audiograms conducted at an average interval of 448.0 d after AAT revealed a prevalence of long-term HL exceeding 20%. Higher doses of corticosteroid therapy (>1 mg/kg) were associated with a reduced frequency of long-term HL.
CONCLUSIONS: This study highlights the prevalence of long-term hearing impairment after AAT in the French military. The findings emphasize the importance of preventive measures, including proper use of hearing protection devices, and the need for timely diagnosis and treatment. Further research is warranted to explore gender susceptibility to AAT and evaluate the impact of different weapons on AAT characteristics. The study also underscores the potential benefits of higher doses of corticosteroid therapy in reducing the risk of long-term hearing impairment. Overall, the findings contribute to a better understanding of AAT and can inform strategies for its prevention and management in military settings.
Abstract of the disclosure:  This invention relates to methods for detecting, iden-tifying and quantifying enzymes, for example, human pro-teolytic enzymes.  The method broadly comprises forming an immobilized or insoluble complex comprising enzyme, enzyme inhibitor and enzyme inhibitor-antibody reactive site and then detecting and identifying, preferably quan-titatively, one or more enzymes bound to the complex.     In a preferred embodiment, a matrix, e.g. solid or semisolid surface or permeable matrix, has affixed thereto enzyme inhibitor-antibody or an immunologically active (inhibitor binding) fragment of such an antibody.  This insoluble enzyme inhibitor interacting matrix is then con-tacted with biological fluid, e.g. body fluid, to bind one or more predetermined enzyme inhibitor-enzyme complexes, if present in the biological fluid.  The bound enzyme is then detected, identified and preferably quantified.
Sunitinib is administered in oral capsules of 12.5 mg. Patients will start with a continuous once-daily dose of 37.5 mg.
In some embodiments, a non-transitory processor-readable medium stores code representing instructions to be executed by a processor. The code includes code to cause the processor to receive a plurality of sets of images associated with a sample treated with fluorescence in situ hybridization (FISH) probes. Each image from that set of images is associated with a different focal length using a fluorescence microscope. Each FISH probe can selectively bind to a unique location on chromosomal DNA in the sample. The code further causes the processor to identify cell nuclei in the images. The code further causes the processor to apply a convolutional neural network (CNN) to each set of images. The CNN is configured to identify a probe indication from a plurality of probe indications for that set of images. The code further causes the processor to identify the sample as containing circulating tumor cells.
Locally advanced or metastatic urothelial carcinoma is a genomically and molecularly heterogeneous disease associated with various clinical outcomes. We aimed to evaluate the association between the status of p53/FGFR3 expression and the efficacy of enfortumab vedotin (EV) in metastatic urothelial carcinoma. We evaluated the association between p53 (abnormal vs. wild-type) or FGFR3 (high vs. low) expression determined by immunohistochemistry and response to EV in 28 patients with metastatic urothelial carcinoma. Overall, 60.7% showed abnormal p53, and 17.9% had high FGFR3 expression. The rates of objective response to EV were statistically higher in patients with abnormal p53 than in those with wild-type p53 (p = 0.038). Patients with pure urothelial carcinoma (n = 18) and low FGFR3 showed significantly better response to EV than those with high FGFR3. When the statuses of p53 and FGFR3 were combined, abnormal p53/low FGFR3 (vs. wild-type p53/high FGFR3) was strongly associated with favorable outcomes in both the entire cohort (p = 0.002) and in cases of pure urothelial carcinoma only (p = 0.023). Immunohistochemically abnormal p53 tumors were found to respond well to EV, while high FGFR3 tumors had a poorer response. Thus, p53 and FGFR3 are potential biomarkers for predicting response to EV treatment in patients with urothelial carcinoma.
PURPOSE:To rapidly necrose.reduce malignant tumorous cells and effectively treat malignant tumors, etc., by bringing blood plasma or serum of a living body having malignant tumors into contact with a specific compound capable of activating C3 in a complement activation route and administering the resultant activated blood plasma or serum to a living body. CONSTITUTION:Blood plasma or serum obtained from a living body having malignant tumors is brought into contact with one or more compounds selected from (i) high polymers, e.g. polyacrylic acid, etc., capable of forming negative charge, (ii) polysaccharides, e.g. crosslinked dextran, etc., having branched chains, (iii) acidic polysaccharides, e.g. sodium alginate, etc., and (iv) lipopolysaccharide inulin and/or zymosan preferably insolubilized by carrying on an inert carrier and then injected into a living body identical to or of the same species as the above-mentioned living body to rapidly necrose.reduce the malignant tumors, etc. Furthermore, since the blood plasma or serum is readily treated by this method, treatment of the malignant tumors, etc., can be simply and surely carried out.